Scott Got­tlieb takes a turn in the spot­light for FDA can­di­dates; Tri­umphant Achao­gen lines up stock sale

Reuters has stum­bled on to the news that Scott Got­tlieb is un­der con­sid­er­a­tion by the Trump team for new chief of the FDA. Most of the rest of the bio­phar­ma world, though, was well aware that the Re­pub­li­can stal­wart would fac­tor in as a top can­di­date for this po­si­tion, which he has been prep­ping for through­out the Oba­ma ad­min­is­tra­tion’s 8-year term. The re­cent brouha­ha over re­ports that Pe­ter Thiel as­so­ciate Jim O’Neill – who has ex­pressed some rad­i­cal ideas on ap­prov­ing new drugs on safe­ty da­ta alone – may well have helped Got­tlieb’s po­si­tion as the more ac­cept­able fig­ure for the post.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.